Edition:
United States

Quidel Corp (QDEL.O)

QDEL.O on Nasdaq

46.93USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$46.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
425,499
52-wk High
$47.60
52-wk Low
$18.25

Latest Key Developments (Source: Significant Developments)

Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets
Monday, 27 Nov 2017 12:40pm EST 

Nov 27 (Reuters) - Quidel Corp ::QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS.CO ‍ACKNOWLEDGED BECKMAN COULTER PLANS TO PURSUE COMMERCIAL LITIGATION TO ALLOW IT TO SELL BNP DIRECTLY.‍IN RECENT WEEKS, BOARD REJECTED OFFERS BY DANAHER CORP TO BUY BNP ASSAY BUSINESS​.‍BOARD FOUND THAT DANAHER'S PROPOSAL WAS "INADEQUATE" FOR BNP ASSAY BUSINESS​.  Full Article

Quidel Corp reports Q3 GAAP loss per share $0.16
Wednesday, 1 Nov 2017 04:10pm EDT 

Nov 1 (Reuters) - Quidel Corp ::Quidel reports third quarter 2017 financial results.Q3 gaap loss per share $0.16.Q3 revenue $50.9 million versus I/B/E/S view $50.3 million.Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.Q3 non-gaap earnings per share $0.17.  Full Article

Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA
Monday, 23 Oct 2017 08:30am EDT 

Oct 23 (Reuters) - Quidel Corp :Quidel receives FDA clearance for its point-of-care Sofia® Lyme FIA.Quidel - ‍Sofia Lyme FIA is for detecting human antibodies to Borrelia burgdorferi from serum & plasma specimens from patients with B. burgdorferi infection​.  Full Article

Quidel gets FDA nod for Solana Assay molecular diagnostic test
Tuesday, 17 Oct 2017 08:30am EDT 

Oct 17 (Reuters) - Quidel Corp :Quidel receives FDA clearance for its Solana RSV + hMPV Assay.Quidel corp - ‍received clearance from U.S. FDA to market its solanarespiratory syncytial virus + human metapneumovirus assay​.  Full Article

QUIDEL ANNOUNCES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD ON DEAL FOR ALERE'S ASSAY BUSINESS
Thursday, 28 Sep 2017 02:00pm EDT 

Sept 28 (Reuters) - Quidel Corp ::QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS.QUIDEL-GETS NOTICE FROM FTC GRANTING EARLY TERMINATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO ACT FOR CO'S PENDING ACQUISITION OF ALERE'S ASSAY BUSINESS.QUIDEL - CO'S ACQUISITION OF ALERE'S TRIAGE METERPRO BUSINESS IS NOT AFFECTED BY EARLY TERMINATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO.  Full Article

Quidel Q2 GAAP loss per share $0.35
Wednesday, 26 Jul 2017 04:10pm EDT 

July 26 (Reuters) - Quidel Corp ::Quidel reports second quarter 2017 financial results.Q2 GAAP loss per share $0.35.Q2 revenue $38.3 million versus I/B/E/S view $41.8 million.Q2 non-GAAP loss per share $0.12.Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Quidel announces definitive agreement to acquire Alere Triage assets
Monday, 17 Jul 2017 06:00am EDT 

July 17 (Reuters) - Quidel Corp :Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​.Quidel Corp- ‍transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - to buy Triage business and B-type Naturietic Peptide (BNP) business for a total consideration of $400 million plus $40 million in contingent consideration​.Quidel Corp - ‍transactions are to be financed with cash plus committed financing from Bank of America Merrill Lynch and J.P. Morgan Chase Bank.Quidel Corp - ‍Quidel will distribute Triage MeterPro products and BNP assays through a combination of direct sales force and distributors​.  Full Article

Quidel receives the CE mark for its thyretain tbi reporter bioassay
Wednesday, 7 Jun 2017 06:00pm EDT 

June 7 (Reuters) - Quidel Corp ::Quidel receives the CE mark for its thyretain® tbi reporter bioassay.  Full Article

Quidel gets FDA clearance, CLIA waiver for Sofia 2 Immunoassay analyzer
Tuesday, 30 May 2017 02:15pm EDT 

May 30 (Reuters) - Quidel Corp ::Quidel receives FDA clearance and CLIA waiver for its point-of-care Sofia 2 Immunoassay analyzer for use with Sofia Influenza A+B Assay.  Full Article

Quidel receives PMDA approval for its point-of-care SOFIA Influenza A+B Assay
Wednesday, 24 May 2017 06:30pm EDT 

May 24 (Reuters) - Quidel Corp :Quidel receives PMDA approval for its point-of-care Sofia Influenza A+B Assay.Approval from Japan's PMDA for Sofia Influenza A+B fluorescent immunoassay to be used with Sofia Fluorescent Immunoassay Analyzer.  Full Article

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )